Caroline S Foo
Overview
Explore the profile of Caroline S Foo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Acar D, Witkowski W, Wejda M, Wei R, DeSmet T, Schepens B, et al.
EBioMedicine
. 2024 Jan;
100:104960.
PMID: 38232633
Background: SARS-CoV-2-neutralizing antibodies (nABs) showed great promise in the early phases of the COVID-19 pandemic. The emergence of resistant strains, however, quickly rendered the majority of clinically approved nABs ineffective....
2.
Sharma S, Vercruysse T, Sanchez-Felipe L, Kerstens W, Rasulova M, Bervoets L, et al.
Nat Commun
. 2022 Nov;
13(1):6644.
PMID: 36333374
Current COVID-19 vaccines are based on prototypic spike sequences from ancestral 2019 SARS-CoV-2 strains. However, the ongoing pandemic is fueled by variants of concern (VOC) escaping vaccine-mediated protection. Here we...
3.
Assmus F, Driouich J, Abdelnabi R, Vangeel L, Touret F, Adehin A, et al.
Microorganisms
. 2022 Aug;
10(8).
PMID: 36014057
In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on...
4.
Abdelnabi R, Foo C, Kaptein S, Boudewijns R, Vangeel L, De Jonghe S, et al.
J Virol
. 2022 Aug;
96(16):e0075822.
PMID: 35924921
Ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lacks the intrinsic ability to bind to the mouse ACE2 receptor, and therefore establishment of SARS-CoV-2 mouse models has been limited to...
5.
Fenwick C, Turelli P, Ni D, Perez L, Lau K, Herate C, et al.
Nat Microbiol
. 2022 Jul;
7(9):1376-1389.
PMID: 35879526
The SARS-CoV-2 Omicron variant has very high levels of transmission, is resistant to neutralization by authorized therapeutic human monoclonal antibodies (mAb) and is less sensitive to vaccine-mediated immunity. To provide...
6.
McCafferty S, Haque A, Vandierendonck A, Weidensee B, Plovyt M, Stuchlikova M, et al.
Mol Ther
. 2022 Apr;
30(9):2968-2983.
PMID: 35450821
Self-amplifying RNA vaccines may induce equivalent or more potent immune responses at lower doses compared to non-replicating mRNA vaccines via amplified antigen expression. In this paper, we demonstrate that 1 ...
7.
Foo C, Abdelnabi R, Kaptein S, Zhang X, Ter Horst S, Mols R, et al.
Antiviral Res
. 2022 Apr;
202:105311.
PMID: 35390430
Nelfinavir is an HIV protease inhibitor that has been widely prescribed as a component of highly active antiretroviral therapy, and has been reported to exert in vitro antiviral activity against...
8.
Foo C, Abdelnabi R, Vangeel L, De Jonghe S, Jochmans D, Weynand B, et al.
Microorganisms
. 2022 Mar;
10(3).
PMID: 35336208
Ivermectin, an FDA-approved antiparasitic drug, has been reported to have in vitro activity against SARS-CoV-2. Increased off-label use of ivermectin for COVID-19 has been reported. We here assessed the effect...
9.
Abdelnabi R, Foo C, Jochmans D, Vangeel L, De Jonghe S, Augustijns P, et al.
Nat Commun
. 2022 Feb;
13(1):719.
PMID: 35169114
There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed...
10.
Abdelnabi R, Foo C, Zhang X, Lemmens V, Maes P, Slechten B, et al.
Antiviral Res
. 2022 Jan;
198:105253.
PMID: 35066015
The emergence of SARS-CoV-2 variants of concern (VoCs) has exacerbated the COVID-19 pandemic. End of November 2021, a new SARS-CoV-2 variant namely the omicron (B.1.1.529) emerged. Since this omicron variant...